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Abstract
Human immunodeficiency virus type 1 (HIV-1) infection of the central nervous system (CNS) can lead to the development of
HIV-1-associated dementia (HAD). We examined the virological characteristics of HIV-1 in the cerebrospinal fluid (CSF) of
HAD subjects to explore the association between independent viral replication in the CNS and the development of overt
dementia. We found that genetically compartmentalized CCR5-tropic (R5) T cell-tropic and macrophage-tropic HIV-1
populations were independently detected in the CSF of subjects diagnosed with HIV-1-associated dementia. Macrophage-
tropic HIV-1 populations were genetically diverse, representing established CNS infections, while R5 T cell-tropic HIV-1
populations were clonally amplified and associated with pleocytosis. R5 T cell-tropic viruses required high levels of surface
CD4 to enter cells, and their presence was correlated with rapid decay of virus in the CSF with therapy initiation (similar to
virus in the blood that is replicating in activated T cells). Macrophage-tropic viruses could enter cells with low levels of CD4,
and their presence was correlated with slow decay of virus in the CSF, demonstrating a separate long-lived cell as the source
of the virus. These studies demonstrate two distinct virological states inferred from the CSF virus in subjects diagnosed with
HAD. Finally, macrophage-tropic viruses were largely restricted to the CNS/CSF compartment and not the blood, and in one
case we were able to identify the macrophage-tropic lineage as a minor variant nearly two years before its expansion in the
CNS. These results suggest that HIV-1 variants in CSF can provide information about viral replication and evolution in the
CNS, events that are likely to play an important role in HIV-associated neurocognitive disorders.
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Introduction
Human immunodeficiency virus type 1 (HIV-1) infects CD4
+ T
cells in the blood and lymphoid organs. In addition, infection of
the central nervous system (CNS) can result in mild to severe
neurological disease, including HIV-1-associated dementia (HAD)
[1]. Although the incidence of HAD and minor cognitive motor
disorder have been significantly reduced following the introduction
of highly active antiretroviral therapy (HAART), these disorders
continue to affect a substantial proportion of the HIV-1-infected
population [2,3]. The insufficient CNS penetration of some
antiretroviral drugs or viral resistance may allow HIV-1 to persist
in the CNS during the course of therapy [4,5,6,7]. The success of
HAART has led to an increased lifespan and an older
demographic of HIV-infected subjects, and these subjects in
particular have an increased risk of developing HAD due to their
enhanced age [8,9]. Less severe neurological problems associated
with HIV-1 infection such as minor cognitive impairments may
also be increasing [10,11], indicating that neurological disorders
will remain a problem for HIV-1-infected subjects in the future.
Finally, unequal access to HAART and the potential of CNS
involvement prior to the initiation of HAART makes the question
of HIV replication in the CNS relevant to many infected people.
Several lines of evidence suggest that some HAD subjects can
harbor macrophage-tropic HIV-1 variants [12,13,14,15,16,17], a
distinct phenotype associated with the ability to infect cells with
low surface expression of CD4. The initiation of antiretroviral
therapy results in rapid decay of virus in the blood, which is
associated with virus replicating in activated CD4
+ T cells [18,19];
however, HIV-1 in the cerebrospinal fluid (CSF) can decay slowly
with the initiation of therapy in some subjects with HAD,
suggesting a longer-lived cell type as the origin of this virus
[20,21,22]. Macrophage tropism does not appear to be a feature of
the transmitted variants of HIV-1 [23,24], leaving open the
question of when and where macrophage-tropic variants of HIV
arise and their role in HIV-1-associated pathogenesis.
Previous studies have reported that HIV-1 populations in the
CSF of HAD subjects have increased viral genetic compartmen-
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distinct HIV-1 variants have been detected at autopsy in the CNS
of some subjects with HAD [27,28,29], suggesting that autono-
mous viral replication is occurring in the CNS of subjects with
more severe neurological disease. We examined HIV-1 variants in
the CSF of HAD subjects to determine the viral genotypes and
phenotypes associated with the development of HAD. Here we
show that genetically compartmentalized CCR5-tropic (R5) T
cell-tropic and macrophage-tropic HIV-1 populations are inde-
pendently found in the CSF of subjects diagnosed with HIV-1-
associated dementia. Our results demonstrate that HIV-1 can
replicate in at least two cell types within the CNS in association
with the development of dementia. Macrophage-tropic viruses
were poorly represented in the blood population, highlighting the
restricted, tissue-specific host range of these variants.
Results
HIV-1 genetic compartmentalization and evolution of viral
populations between the peripheral blood and CSF of HAD and
non-HAD subjects were assessed using single genome amplification
(SGA) of the viral env gene [30] and phylogenetic analyses (Table 1
and Table 2). Phenotypic characteristics of compartmentalized HIV-
1 env genes from subjects with and without HIV-1-associated
neurological diseasewere alsomeasured to assess the entry phenotype
of the compartmentalized virus. HIV-1 env genes were used to
generate pseudotyped luciferase reporter viruses, which were then
used to infect 293-Affinofile cells [31] with differential CD4 surface
expression, and to infect monocyte-derived macrophages (MDM).
Coreceptor tropism analysis revealed that most of the HIV-1 Env
proteins were CCR5-tropic, including all of the Env proteins
representing compartmentalized virus from the CSF (Table S1).
HIV-1 variants in the CSF of neurologically asymptomatic
subjects can be R5 T cell-tropic
A range of genetic compartmentalization (0–43% of the total
CSF sequences) was detected in the CSF HIV-1 populations of
three neurologically asymptomatic subjects (Figure 1A and
Table 2), which is consistent with reports from previous studies
showing low but variable compartmentalization in asymptomatic
subjects [26,32]. Viruses pseudotyped with Env proteins derived
from virus in the blood plasma and CSF of these neurologically
asymptomatic subjects could only infect cells with high CD4
surface expression (Figure 1B; Table S1). In addition, most Env-
pseudotyped viruses did not efficiently infect MDM (Figure 1C),
although subject 4030 Env C23 infected about half as efficiently as
the macrophage-tropic Ba-L envelope. This indicates that these
viruses require the higher levels of surface CD4 found on activated
CD4
+ T cells for entry into target cells. While this represents a
small sample size, this analysis demonstrates that T cell-tropic R5
viruses can be found in the CSF.
Compartmentalized R5 T cell-tropic and macrophage-
tropic HIV-1 populations are independently found in the
CSF of subjects diagnosed with HIV-1-associated
dementia
Significant genetic compartmentalization was detected between
the blood plasma and CSF HIV-1 populations of eight subjects
diagnosed with HIV-1-associated neurological disease (Figure 2
and Figure 3; Table 2). We have previously shown that these
subjects comprise two groups with respect to the rate of decay of
compartmentalized virus in the CSF during the initiation of
antiretroviral therapy: rapid decay in subjects 4033, 4051, 5003,
7036; and slow decay in subjects 4013, 4059, 5002, 7115 [20].
Phylogenetic analyses of the blood and CSF-derived virus in these
subjects revealed significant compartmentalization and genetic
distance between the blood plasma and CSF viral populations
(Table 2; Figure 2A and Figure 3), indicating that sustained HIV-1
replication was likely occurring in the CNS of subjects with severe
neurological disease. The detection of substantial compartmental-
ization in the HAD subjects was significant when compartmen-
talization versus an equilibrated population was compared to a
model where each was equally likely (P=0.03, Chi-squared test),
or in comparison to the modest compartmentalization in the three
asymptomatic subjects (P=0.02, Fisher’s Exact test).
Clonal amplification of a specific viral lineage was identified for
CSF variants that were separated phylogenetically from the plasma
virus population in three HAD subjects (subjects 4033, 5003, and
7036; Figure 2) who also had rapid decay of compartmentalized virus
in the CSF [20]. The clonal amplification was seen as decreased env
diversity in the CSF viral population, defined as having an average env
pairwisedistance ,0.01(seeTable 2),and shortbranchlengthsinthe
phylogenetic tree, both indicative of a recent expansion of a single
variant. Clonal amplification of the CSF-compartmentalized HIV-1
population was associated with elevated CSF pleocytosis (Table 1;
P=0.036 using a two-tailed Mann-Whitney test). We found that the
clonally amplified, compartmentalized HIV-1 variants were not able
to infectcells expressing a low surface density of CD4 (Figure 2B) and
did not efficiently infect MDM (Figure 2C), indicating that for these
subjects the CSF-compartmentalized viruses were replicating in
activated T cells.
Phylogenetic analysis showed significant compartmentalization
between the blood plasma and CSF HIV-1 populations, and a more
genetically complex viral CSF population, for the remaining five
subjects with neurological disease (subjects 4013, 4051, 4059, 5002,
and 7115; Figure 3). We demonstrated in a previous study that these
subjects had slow decay of compartmentalized virus in the CSF after
the initiation of antiretroviral therapy, although subject 4051 had
rapid decay detected in the CSF due to a complex viral population
and only partial compartmentalization of CSF virus [20]. Compart-
Author Summary
Human immunodeficiency virus type 1 (HIV-1) infection of
the central nervous system (CNS) can lead to the
development of a severe neurological disease termed
HIV-1-associated dementia (HAD). Individuals diagnosed
with HAD commonly have genetically distinct HIV-1
variants in their cerebrospinal fluid (CSF) that are not
detected in the blood virus population, suggesting that
independent viral replication is occurring in the CNS of
HIV-1-infected subjects with severe neurological disease.
We examined HIV-1 variants in the blood plasma and CSF
of HAD subjects to determine the viral characteristics
associated with the development of dementia during HIV-
1 infection. We found that genetically distinct HIV-1
variants in the CSF of HAD subjects were either R5 T cell-
tropic or macrophage-tropic. The R5 T cell-tropic viruses
required high levels of the cellular surface receptor CD4 to
enter cells, while macrophage-tropic viruses could enter
cells with low levels of CD4, suggesting that HIV-1 can
replicate in at least two cell types within the CNS during
the course of dementia. Finally, macrophage-tropic viruses
were detected in the CSF but poorly represented in the
blood virus population. Our results suggest that HIV-1
variants in the CSF can provide information about
independent viral replication in the CNS during the course
of HIV-1 infection.
HIV-1 in the CNS Replicates in Multiple Cell Types
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efficiently infected cells with a low CD4 surface density (Figure 4A),
andtheseEnvproteinsweremacrophage-tropicbasedontheirability
to infect MDM (Figure 4B). In contrast, most HIV-1 Env proteins
derived from the blood of these subjects were not able to mediate
infection of cells with low CD4 surface expression and could only
infect cells with high CD4 levels (Figure 4), indicating adaptation for
replication in activated T cells in the peripheral blood. However, a
macrophage-tropic lineage was detected in the blood plasma of
subject 4059 (Figure 3 and Figure 4), consistent with the previous
observation that it is possible to isolate macrophage-tropic viruses
from the blood of some subjects in late-stage disease [12], although
this lineage was genetically distinct from that found in the CSF. The
absence of the CNS macrophage-tropic virus lineage from the blood
in the five subjects with macrophage-tropic virus in the CSF was
statistically significant (P=0.03, Chi-squared test). Finally, in the
subjects with significant CSF compartmentalization there was a
perfect correlation between the presence of R5 T cell-tropic virus and
rapid viral load decay in the CSF, and with macrophage-tropic virus
and slow viral decay in the CSF (P=0.03, Fisher’s Exact test).
Macrophage-tropic HIV-1 variants in the CSF/CNS viral
population can be detected prior to the development of
overt, severe dementia
We further examined macrophage-tropic and R5 T cell-tropic
viral population dynamics in the CNS by conducting longitudinal
env genotypic and phenotypic analyses for two subjects who
progressed to HAD (Figure 5 and Figure S1). We detected a
clonally amplified, compartmentalized R5 T cell-tropic population
in the CSF of subject 7036 at the time of HAD diagnosis, but this
population was not present in the CSF prior to the diagnosis of
dementia (Figure S1), suggesting rapid expansion of a discrete viral
population around the time of diagnosis. In addition, CSF viral
populations at sampling time points prior to HAD diagnosis (10/
31/2002 and 4/28/2003) were less compartmentalized, similar to
CSF populations detected in neurologically asymptomatic subjects
(Table 2). Clinical assessment also revealed a dramatic increase in
CSF viral load and CSF neopterin, a pteridine associated with
intrathecal immunoactivation [33,34], over the study period
(Table 1 and Figure S2A), which correlated with both the decline
in neurological function from nearly asymptomatic to HAD (see
QNPZ-4 scores in Table 1), and with the rapid expansion of a
compartmentalized R5 T cell-tropic HIV-1 population in the CSF
at this time-point.
The other subject (7115) had a compartmentalized macro-
phage-tropic HIV-1 population present in the CSF at the time of
dementia diagnosis. We identified a macrophage-tropic lineage in
the CSF of this subject (Figure 5A) spanning a period of
approximately two years prior to the diagnosis of severe dementia
[see clones C17 (221) and C17 (216)]. All of the HIV-1 env genes
tested from this lineage encoded Env proteins that were
macrophage-tropic based on the ability to infect cells with a low
CD4 surface expression (Figure 5B), and the ability to infect MDM
Table 1. Subject population clinical and virological characteristics.
Cell counts (cells/ml) HIV-1 RNA (log10 copies/ml)
Subject ID Sample date CD4 CSF WBC
a Plasma CSF ADC Stage
b QNPZ-4
c
Comp. virus
phenotype
d CSF Decay
e
4012 9/3/1997 295 16 5.18 4.39 0 20.9 N/A 1.73
4030 9/16/1999 239 4 4.86 4.06 0 0.7 N/A 1.83
4021 11/5/1998 215 0 4.97 4.02 0 20.2 N/A 1.64
4033 1/12/2000 173 28 4.83 5.23 2 24.6 T-tropic 1.68
5003 11/3/1997 234 46 3.31 4.33 3 24.0 T-tropic 1.21
7036 10/31/2002 327 20 4.67 3.89 0 20.4 N/A
4/28/2003 324 30 4.97 4.41 0 20.8 N/A
2/18/2004 267 240 5.12 5.37 2 22.3 T-tropic 3.34
4051 8/20/2004 344 12 5.61 5.41 3 26.4 M-tropic 2.39
4013 11/17/1997 148 10 4.62 4.75 1 21.6 M-tropic 9.5
4059 8/16/2006 53 1 5.31 5.08 3 26.7 M-tropic 9.42
5002 10/17/1997 59 4 4.24 5.32 3 27.0 M-tropic No decay
7115 7/8/2002 145 7 4.68 4.43 U 21.5 M-tropic
12/3/2002 108 24 4.76 4.85 U 21.5 M-tropic
4/8/2004 50 12 5.87 4.85 2 26.2 M-tropic
5/11/2004 66 6 3.46 4.63 2 28.4 M-tropic 13.58
6/3/2004 150 7 2.97 3.54 3 25.0 N/A
aCSF white blood cell counts.
bAIDS dementia complex staging [1] conformed to the American Academy of Neurology criteria used at the time of diagnosis, and would also conform to current
criteria for HAD diagnosis based on the degree of functional impairment in both cognitive and motor spheres. 0, neurologically asymptomatic; 1, mild neurological
impairment; 2–3, moderate to severe HAD; U, uncertain ADC stage determination related to confounding conditions, see text for further discussion.
cMean change from baseline (score of 0.0) of a four-item quantitative neurological performance battery score.
dCompartmentalized HIV-1 population phenotype. M-tropic, macrophage-tropic; T-tropic, R5 T cell-tropic; N/A, not applicable.
eHalf-life in days of total viral RNA decay in the CSF after the initiation of antiretroviral therapy. The decay rate is listed next to the sample date that was closest to the
date when therapy was initiated. Data summarized from ref. [20]. Subject antiretroviral drug regimens and CNS penetration effectiveness rank calculations for drug
regimens, and CSF-compartmentalized variant decay calculations are described in detail in ref. [20].
doi:10.1371/journal.ppat.1002286.t001
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time-point encoded proteins that were T cell-tropic. The viral
sequences in the CSF from the macrophage-tropic lineage
increased as a fraction of the population over time, especially
between the time of HAD diagnosis and one month later.
Neurological assessment of subject 7115 several years prior to
HAD diagnosis revealed slightly impaired neurological perfor-
m a n c e( s e eQ N P Z - 4s c o r e si nT a b l e1 ) ,a n dC S Fv i r a ll o a da n d
neopterin were fairly stable over the two-year course of the
study (Table 1 and Figure S2B), perhaps indicating earlier onset
of mild neurological disease, although this subject had other
confounding conditions including drug use and psychiatric
disease. These confounding factors precluded an AIDS demen-
tia complex (ADC) stage determination at earlier sampling time-
points (7/8/2002 and 12/3/2002), although this subject was
considered ADC stage 0 if this could be applied. Neurological
performance markedly declined at the time of dementia
diagnosis (QNPZ-4 of 26.2) and continued to decline
thereafter. Taken together, our data indicate that in this subject
macrophage-tropic HIV-1 variants existed as minor variants
within a specific evolutionary lineage of the CSF/CNS viral
population and eventually became the dominant CSF popula-
tion, suggesting that confounding factors may have obscured an
understanding of the potential earlier contribution of HIV-
related CNS dysfunction. Neurocognitive impairment can result
from multiple factors, and knowledge about viral replication in
the CNS, as viewed through virus in the CSF, can provide
insight about the potential contribution of HIV-1 to the
neurological status of the patient.
Discussion
We have demonstrated that genetically compartmentalized R5
T cell-tropic and macrophage-tropic HIV-1 populations are
independently found in the CSF of subjects diagnosed with
HIV-1-associated dementia. Our study was limited to a cohort of
eight subjects with neurological disease who were receiving lumbar
punctures at the time of HAD diagnosis and while initiating
therapy, with samples available prior to therapy in two subjects
followed longitudinally. In spite of a relatively small sample size we
were able to link several features that distinguish two different
virological states associated with severe neurological dysfunction.
Compartmentalized HIV-1 populations in the CSF with R5 T
cell-tropic entry phenotypes were separated phylogenetically from
plasma virus populations, and were associated with clonal
amplification of the CSF viral population. Replication in CD4
+
T cells is consistent with both the rapid decay of compartmen-
talized virus in the CSF after the initiation of therapy in these
subjects, and the migration of immune cells into the CNS/CSF as
indicated by the presence of elevated CSF pleocytosis. Compart-
Table 2. HIV-1 population characteristics in the CSF compartment.
SGA amplicons Slatkin-Maddison
c
Subject ID
Sample
date Plasma CSF % Comp. [95% CI]
a
Comp. env avg.
pairwise distance
b
Migration
events P-value CSF compartment
d
4012 9/3/1997 24 21 19 [7–41] N/A 13 0.1705 Eq
4030 9/16/1999 41 20 0 [0–19] N/A 15 0.1516 Eq
4021 11/5/1998 27 16 43 [23–67] 0.016 8 0.002 Intermediate
4033 1/12/2000 22 22 64 [43–80] 0.007 9 0.0021 Comp, Amp
5003 11/3/1997 32 17 94 [71–99] 0.003 3 ,0.0001 Comp, Amp
7036 10/31/2002 40 13 23 [7–51] 0.002 8 0.0049 Intermediate, Amp
4/28/2003 38 30 0 [0–13] N/A 23 0.7113 Eq
2/18/2004 27 25 92 [74–99] 0.002 3 ,0.0001 Comp, Amp
4051 8/20/2004 25 29 48 [31–66] 0.03 15 0.0908 Intermediate
4013 11/17/1997 33 24 83 [64–94] 0.023 5 ,0.0001 Comp
4059 8/16/2006 27 20 97 [81–99] 0.029 2 ,0.0001 Comp
5002 10/17/1997 21 20 90 [69–98] 0.017 3 ,0.0001 Comp
7115 7/8/2002 35 25 44 [27–63] 0.002 14 0.0083 Amp
12/3/2002 20 21 62 [41–79] 0.031 10 0.0256 Intermediate
4/8/2004 22 19 21 [8–44] N/A 13 0.3956 Eq
5/11/2004 19 17 100 [78–100] 0.02 2 ,0.0001 Comp
6/3/2004 N/A 3 N/A N/A N/A N/A N/A
aThe percent of CSF env sequences that were compartmentalized at each sampling time point. CSF env sequences were considered compartmentalized based on
maximum-likelihood phylogenetic tree structures and strong bootstrap support. The 95% confidence intervals were calculated for the proportion of CSF-
compartmentalized env sequences using the modified Wald method.
bThe classification of clonal amplification was determined by calculating the average overall pairwise distance (nucleotide substitutions per site) between env sequences
in the compartmentalized HIV-1 population. A CSF-compartmentalized HIV-1 population with an average pairwise distance ,0.01 was considered to have clonal
amplification. N/A, not applicable.
cThe Slatkin-Maddison test for gene flow between populations was used to measure genetic compartmentalization between the blood plasma and CSF HIV-1
populations. Migration events describe the number of env migration events between the blood plasma and CSF HIV-1 populations for each phylogenetic tree. A P-
value ,0.05 indicates statistically significant genetic compartmentalization between the blood plasma and CSF HIV-1 populations.
dHIV-1 population characteristics in the CSF compartment. Eq, equilibration with the blood plasma; Intermediate, a subpopulation of the CSF is compartmentalized;
Comp, significant compartmentalization in the CSF; Amp, clonal amplification of variants detected in the CSF; N/A, not applicable.
doi:10.1371/journal.ppat.1002286.t002
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PLoS Pathogens | www.plospathogens.org 4 October 2011 | Volume 7 | Issue 10 | e1002286Figure 1. HIV-1 variants in the CSF of neurologically asymptomatic subjects can be R5 T cell-tropic. (A) Maximum-likelihood
phylogenetic trees. env sequences from the CSF are labeled with solid blue circles, and plasma sequences are labeled with solid red triangles.
Bootstrap numbers $70 are indicated with an asterisk at the appropriate nodes, and bootstrap values are listed at critical nodes in the trees. The
genetic distance scale bar indicates the number of nucleotide substitutions per site between env sequences. HIV-1 env sequences selected for
phenotypic analyses are indicated with a black square, and X4-tropic envelopes are indicated with an underlined, superscript ‘‘X’’ following the
envelope name; all other envelopes were R5-tropic. (B) Single-cycle infection of HIV-1 Env-pseudotyped reporter viruses on CD4
lowCCR5
high 293-
Affinofile cells. Receptor expression was measured as follows: CD4
low=1,214 receptors/cell, CD4
high=97,003 receptors/cell, CCR5
high=34,431
receptors/cell. Data are expressed as means of quadruplicate wells 6 s.d., and results are representative of two independent experiments. (C) Single-
cycle infection of HIV-1 Env-pseudotyped reporter viruses on primary human MDM. Data shown are means of duplicate wells 6 s.d. for one donor,
and were normalized to infection of the control macrophage-tropic HIV-1 Ba-L envelope.
doi:10.1371/journal.ppat.1002286.g001
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PLoS Pathogens | www.plospathogens.org 5 October 2011 | Volume 7 | Issue 10 | e1002286Figure 2. Compartmentalized R5 T cell-tropic HIV-1 populations are found in the CSF of subjects diagnosed with HAD. (A) Maximum-
likelihood phylogenetic trees with compartmentalization and clonal amplification in the CSF. env sequences from the CSF are labeled with solid blue
circles, and plasma sequences are labeled with solid red triangles. The phylogenetic tree characteristics are the same as those stated in Figure 1A. (B)
Single-cycle infection of HIV-1 Env-pseudotyped reporter viruses on CD4
lowCCR5
high 293-Affinofile cells. Receptor expression was measured as
follows: CD4
low=1,214 receptors/cell, CD4
high=97,003 receptors/cell, CCR5
high=34,431 receptors/cell. Data are expressed as means of quadruplicate
wells 6 s.d., and results are representative of two independent experiments. (C) Single-cycle infection of HIV-1 Env-pseudotyped reporter viruses on
primary human MDM. Data shown are means of duplicate wells 6 s.d. for one donor, and were normalized to infection of the control macrophage-
tropic HIV-1 Ba-L envelope.
doi:10.1371/journal.ppat.1002286.g002
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with more genetically diverse viral populations in the CSF, and the
slow decay of virus in the CSF after the initiation of therapy,
indicative of viral replication in a long-lived cell. However, given
the small sample size we cannot provide an accurate estimate of
the relative frequency of each type of virologic state other than to
note that they appeared with similar frequency in this cohort of
eight subjects (three with compartmentalized R5 T cell-tropic
virus, five with compartmentalized macrophage-tropic virus).
Overall we detected a significantly compartmentalized CSF
population in seven of these eight subjects suggesting that virus
outgrowth in the CNS, whether macrophage-tropic or R5 T cell-
tropic, will be a feature in a majority of HAD cases.
HIV-1 replication in the CNS is thought to occur in perivascular
macrophages and/or microglia within the brain parenchyma
[13,35,36]. We found that both R5 T cell-tropic and macro-
phage-tropic HIV-1 populations are independently associated with
clinical dementia. This indicates a more complex interaction
between HIV-1 and the CNS since the genetically compartmen-
talized R5 T-cell tropic viruses are unlikely to be replicating in
macrophages or microglia given their requirement for high levels of
CD4 to enter target cells. During simian immunodeficiency virus
(SIV) infection of macaques, CNS infection is associated with the
presence of infiltrating SIV-specific CD8
+ T cells in the brain, but
infiltrating CD4
+ T cells have not been detected [37]. Trafficking of
CD4
+ T cells has been reported in the CNS during infection of
other neurotropic viruses [38,39]. We propose that the presence of
viral antigen, especially during periods of increased HIV-1
replication in the CNS/CSF compartment, could drive the
migration of both CD8
+ and CD4
+ T cells into the CNS/CSF
(resulting in elevated CSF pleocytosis) and lead to persistence of
compartmentalized virus through replication in the CD4
+ T cells,
andthusthe apparentlossofthiscelltype.Consistent withthe lossof
these cells is the rapid decay of virus in the CSF during the initiation
of therapy, which is considered a marker of viral replication in
activated T cells [18,19].
Figure 4. Compartmentalized HIV-1 populations in the CSF of some HAD subjects are macrophage-tropic. Phenotype data is displayed
for HIV-1 env sequences from Figure 3. (A) Single-cycle infection of HIV-1 Env-pseudotyped reporter viruses on CD4
lowCCR5
high 293-Affinofile cells.
Receptor expression was measured as follows: CD4
low=1,214 receptors/cell, CD4
high=97,003 receptors/cell, CCR5
high=34,431 receptors/cell. Data are
expressed as means of quadruplicate wells 6 s.d., and results are representative of two independent experiments. (B) Single-cycle infection of HIV-1
Env-pseudotyped reporter viruses on primary human MDM. Data shown are means of duplicate wells 6 s.d. for one donor, and were normalized to
infection of the control macrophage-tropic HIV-1 Ba-L envelope.
doi:10.1371/journal.ppat.1002286.g004
Figure 3. Compartmentalized HIV-1 populations in the CSF are associated with HAD. Maximum-likelihood phylogenetic trees are
displayed for five HAD subjects with compartmentalization in the CSF. env sequences from the CSF are labeled with solid blue circles, and plasma
sequences are labeled with solid red triangles. The phylogenetic tree characteristics are the same as those stated in Figure 1A.
doi:10.1371/journal.ppat.1002286.g003
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PLoS Pathogens | www.plospathogens.org 8 October 2011 | Volume 7 | Issue 10 | e1002286Figure 5. Macrophage-tropic HIV-1 variants in the CSF/CNS can be detected prior to the development of severe dementia. (A)
Longitudinal phylogenetic analysis of env sequences from one subject with dementia. The genetic distance scale bar indicates the number of
nucleotide substitutions per site between env sequences. HIV-1 env sequences selected for phenotypic analyses are indicated with a black square,
and the node of divergence for the CSF M-tropic population is indicated with a blue open circle. Bootstrap numbers $70 are indicated with an
asterisk at the appropriate nodes, and bootstrap values are listed at critical nodes in the tree. Months from HAD diagnosis correspond to the
following sample dates: 7/8/2002 (221), 12/3/2002 (216), 4/8/2004 (0), 5/11/2004 (1), and 6/3/2004 (2). (B) Single-cycle infection of HIV-1 Env-
pseudotyped reporter viruses on CD4
lowCCR5
high 293-Affinofile cells. Receptor expression was measured as follows: CD4
low=1,214 receptors/cell,
CD4
high=97,003 receptors/cell, CCR5
high=34,431 receptors/cell. Data are expressed as means of quadruplicate wells 6 s.d., and results are
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Some subjects with dementia exhibit HIV-1 encephalitis (HIVE)
characterized by the presence of multinucleated giant cells of the
macrophage/microglia origin and immunohistochemical evidence of
viral replication [40,41]. Although the incidence of HIVE has
decreased during the HAART era, neuropathological changes in
brain tissue, including glial activation and monocyte/macrophage
infiltration [3,42,43], are still common. Future studies examining HIV-
1 populations in paired blood, CSF, and brain tissue from HAD
subjects with and without neuropathological findings will help
determine whether there are physiological differences in brain
pathology between subjects with R5 T cell-tropic versus macro-
phage-tropic HIV-1 variants as the predominant CSF population.
Also, the appearance of macrophage-tropic viruses largely restricted to
the CNS/CSF compartment is most consistent with the appearance of
these viruses late in the infection time course of HIV-1, representing an
expanded host range of the virus that is initially replicating in activated
T cells. Although severe neurological disease associated with HIV-1
infection has declined in the HAART era, milder forms of neurological
disease are increasing. In this study we detected a significantly
compartmentalized macrophage-tropic HIV-1 population in the CSF
of one subject with more mild neurological dysfunction (subject 4013;
Table 1), illustrating the potential importance of understanding the
correlates of HIV-1-associated neurological dysfunction with CNS/
CSF viral population phenotypes.
HIV replication in the CNS can contribute to neurocognitive
decline, so the ability to detect features of the CSF viral population
associated with viral replication in the CNS may provide new
opportunities to guide interventions prior to the development of
overt neurological disease. In our study, one subject with
longitudinal sampling (subject 7115) had macrophage-tropic
variants present as a minor CSF population prior to the diagnosis
of severe dementia (Figure 5). The application of sequencing
technologies with greater capacity to sample a large number of viral
genomes would allow the identification of minor CSF population
variants, but this approach would rely on genotypic determinants of
macrophage tropism rather than the phenotypic determinants used
in our study. Several sequence determinants in env have been
reported to be associated with macrophage tropism [27,44,45];
however, none of these determinants distinguishes the CSF-derived
macrophage-tropic viruses from the paired blood-derived T cell-
tropic viruses for the subjects in our study. Thus, the evolution of
macrophage-tropic virus likely occurs through multiple pathways
that will require a larger catalog of env sequences to allow reliable
genotypic identification. It remains a possibility that the clonal
amplification of R5 T cell-tropic viruses we detected in three HAD
subjects is obscuring a smaller population of macrophage-tropic
CNS virus, a question that could be addressed using more sensitive
sampling methods. Developing a more complete understanding of
the virological markers of CNS replication, and utilizing deep
sequencing technologies to find minor populations, will provide
opportunities to examine the use of CSF for information about viral
replication in the CNS as a potential predictor of neurological
involvement in the pathogenic process.
Materials and Methods
Ethics statement
This study was conducted according to the principles expressed
in the Declaration of Helsinki. The studies were approved by the
Committee for Human Research at the University of California at
San Francisco, and written informed consent was obtained for the
collection of samples from all subjects or their health care
surrogates when informed consent was not considered possible.
Study subject population
All subjects included in this study were HIV-1-infected
individuals that eventually initiated highly-active antiretroviral
therapy. The subject samples used for viral genetic compartmen-
talization and Env protein phenotypic analyses were collected
during previous studies carried out at the University of California
at San Francisco [46]. Serial blood plasma and cerebrospinal fluid
(CSF) samples were collected from subjects at baseline prior to the
start of therapy and during the initiation of antiretroviral therapy,
and samples were collected longitudinally from subjects 7036 and
7115 for several years prior to the initiation of therapy. Plasma and
CSF HIV-1 RNA concentrations were determined using the
Amplicor HIV Monitor kit (Roche). Blood CD4 and CSF white
blood cell (WBC) counts were performed by the San Francisco
General Hospital Clinical Laboratory using routine methods.
Subjects all underwent standardized neurological testing, including
clinical criteria for diagnosis and staging of ADC. They also
underwent brief quantitative neurological testing using four tests to
derive a normalized score, the QNPZ-4 [47].
Single genome amplification
HIV-1 RNA was isolated from blood plasma and CSF samples as
previously described [20]. Viral RNA was reverse transcribed using
Superscript III Reverse Transcriptase (Invitrogen) with oligo (dT) as
the primer per the manufacturer’s instructions. Single genome
amplification of the full-length HIV-1 env gene through the 39 U3
region was conducted as previously described [30]. Briefly, cDNA
was diluted to endpoint, and nested PCR was conducted using the
Platinum Taq High Fidelity polymerase (Invitrogen). The primers
B5853 UP0 and LTR DN1, and B5957 UP1 and LTR DN1, were
used for the first and second rounds of PCR, respectively [48]. The
SGA amplicons were sequenced from the start of V1 through the
ectodomain of gp41 [Hxb2 numbering of positions 6600–8000].
Phylogenetic and compartmentalization analyses
Nucleotide sequences of the env genes were aligned using Clustal
W [49,50] or MAFFT software [51]. Sequences from each subject
were codon aligned using GeneCutter (Los Alamos HIV-1
database; http://www.hiv.lanl.gov/content/sequence/GENE_
CUTTER/cutter.html). Maximum likelihood phylogenetic trees
were generated using PhyML [52] with the following parameters:
HKY85 nucleotide substitution model, four substitution rate
categories, estimation of the transition/transversion rate ratio,
estimation of the proportion of invariant sites, and estimation of
the gamma distribution parameter [53]. Compartmentalization of
CSF viral populations by sequence was determined using the
Slatkin-Maddison test for compartmentalization [54] by HyPhy
software [55] using 10,000 permutations. Pairwise distance was
calculated for HIV-1 env sequences in the CSF-compartmentalized
population using MEGA 4.1 software [56,57,58].
Construction of HIV-1 env clones
The SGA amplicons used in the cloning procedure were
selected based on each subjects’ phylogenetic tree structure and
representative of two independent experiments. (C) Single-cycle infection of HIV-1 Env-pseudotyped reporter viruses on primary human MDM. Data
shown are means of duplicate wells 6 s.d. for one donor, and were normalized to infection of the control macrophage-tropic HIV-1 Ba-L envelope.
doi:10.1371/journal.ppat.1002286.g005
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additional PCR was conducted to amplify only the full-length
HIV-1 env gene using the Phusion hot start high-fidelity DNA
polymerase (Finnzymes) and the primers B5957F-TOPO (59-
CACCTTAGGCATCTCCTATGGCAGGAAGAAG-39) and
B8904R-TOPO (59-GTCTCGAGATACTGCTCCCACCC-39)
following the manufacturer’s instructions. HIV-1 env amplicons
were then gel purified using the QIAquick gel extraction kit
(Qiagen). The purified HIV-1 env genes were cloned into the
pcDNA 3.1D/V5-His-TOPO expression vector (Invitrogen) using
the pcDNA 3.1 directional TOPO expression kit (Invitrogen) and
MAX Efficiency Stbl2 competent cells (Invitrogen) as per the
manufacturer’s instructions.
Cells
293T and TZM-bl cells were cultured in Dulbecco’s modified
Eagle medium (DMEM) supplemented with 10% fetal bovine
serum (FBS) and 100 mg/ml of penicillin and streptomycin. 293-
Affinofile cells [31] were maintained in DMEM supplemented
with 10% dialyzed FBS (12–14 kD dialyzed; Atlanta biologicals)
and 50 mg/ml blasticidin (D10F/B). The Affinofile cell line was
generously provided by Dr. Ben-Hur Lee. Monocyte-derived
macrophages (MDM) were isolated from Ficoll-purified PBMCs
(Biological Specialty Corporation, Colmar, PA) using the human
monocyte enrichment kit without CD16 depletion (Stemcell
Technologies) as per the manufacturer’s instructions. Following
isolation, MDM were seeded in 48-well tissue culture plates and
cultured for 6 days. MDM were cultured in RPMI 1640 medium
supplemented with 10% FBS, 100 mg/ml of penicillin and
streptomycin, and 10 ng/ml recombinant human macrophage
colony stimulating factor (M-CSF; Gibco).
Env-pseudotyped viruses
Env-pseudotyped luciferase reporter viruses were generated by
co-transfection of 293T cells with 3 mg HIV-1 env expression vector
and 3 mg of the pNL4-3.LucR-E- plasmid (obtained from the NIH
AIDS Research and Reference Reagent Program, Division of
AIDS, NIAID, NIH) [59,60] using the FuGENE 6 transfection
reagent and protocol (Roche). Five hours post-transfection the
medium was changed and the cells were incubated at 37uC for an
additional 48 hours, and viral supernatants were harvested.
Coreceptor tropism analysis
Two hours prior to infection the coreceptor inhibitors TAK-779
[61,62] and bicyclam JM-2987 (hydrobromide salt of AMD-3100)
[63,64,65] (both obtained from the NIH AIDS Research and
Reference Reagent Program, Division of AIDS, NIAID, NIH) were
added to TZM-bl cells at concentrations of 2.5 mMa n d5mMu s i n g
the following conditions for each virus: no drug, TAK-779 only,
AMD-3100 only, and both drugs. Cells were infected in the presence
of drug using 50 ml of viral supernatant per well and spinoculated
(2,000 rpm) for 2 hours at 37uC. Infections were incubated for
48 hours at 37uC, and then the cells were harvested and luciferase
activity was assayed using the Luciferase assay system (Promega). All
infections and conditions were conducted in triplicate.
293-Affinofile cellular surface expression of CD4 and
CCR5
293-Affinofile cell [31] CD4 and CCR5 receptor expression was
induced with tetracycline and ponasterone A (ponA; Invitrogen),
respectively. Cells were induced for 18 hours at 37uC in a matrix
format for a total of 24 induction levels with varying amounts of
tetracycline (0–0.1 mg/ml) and ponA (0–2 mM/ml). Receptor
expression was measured using quantitative fluorescence-activated
cytometry (qFACS). Cells were stained with either phycoerythin
(PE)-conjugated anti-human CD4 antibody (clone Q4120, BD
Biosciences) or PE-conjugated mouse anti-human CCR5 antibody
(clone 2D7, BD Biosciences). CD4 and CCR5 receptor levels were
quantified using QuantiBRITE beads (BD Biosciences).
Single-cycle infection of 293-Affinofile cells
Env-pseudotyped luciferase reporter viruses were initially titered
on 293-Affinofile cells expressing the highest induction levels for
CD4 (0.1 mg/ml tetracycline) and CCR5 (2 mM ponA) surface
expression. The amount of pseudotyped virus used in the single-
cycle Affinofile infection assay was normalized to 1610
6 relative
light units for infection at the highest drug levels tested. All
pseudotyped viruses were used within the linear range of the assay,
and all infection conditions were assayed in quadruplicate.
Two days prior to infection, 96-well black tissue culture plates
were coated with 10% poly-lysine in PBS and seeded with 293-
Affinofile cells (2.5610
4 cells/well). Expression of CD4 and CCR5
was induced the following day by adding varying concentrations of
tetracycline and ponasterone A as described above. Eighteen
hours later, the induction medium was removed and fresh culture
medium containing Env-pseudotyped virus was gently added to
the cells. The infection plates were spinoculated [66] at 2,000 rpm
for 2 hours at 37uC, and incubated for an additional 48 hours at
37uC. Infection medium was then removed and the cells
harvested, and luciferase activity was assayed using the Luciferase
assay system (Promega).
Single-cycle infection of MDM
Env-pseudotyped luciferase reporter viruses were initially titered
on 293-Affinofile cells expressing the highest induction levels for
CD4 (0.1 mg/ml tetracycline) and CCR5 (2 mM ponA) surface
expression. The amount of pseudotyped virus used in the single-
cycle MDM infection assay was normalized to 1610
7 relative light
units for infection at the highest 293-Affinofile drug levels tested.
All pseudotyped viruses were used within the linear range of the
assay, and all infection conditions for MDM were assayed in
duplicate wells.
Env-pseudotyped virus was gently added to MDM in culture
and the infection plates were spinoculated at 1,2006g for 2 hours
at 37uC [66]. Unattached virus was removed from the MDM
cultures by removing the medium gently without disturbing the
cells. The MDM were then washed once with warm PBS
supplemented with 1% fetal bovine serum to remove any residual
virus, and once with warm RPMI 1640 medium supplemented
with 10% fetal bovine serum and 100 mg/ml of penicillin and
streptomycin to remove any remaining PBS/FBS. After the
second wash, RPMI 1640 medium supplemented with 10% FBS,
100 mg/ml of penicillin and streptomycin, and 10 ng/ml M-CSF
was added, and the cells were cultured for 5 days at 37uC. The
culture medium was then removed and the cells were harvested
and luciferase activity was assayed using the Luciferase assay
system (Promega).
Nucleotide sequence accession numbers
The HIV-1 env nucleotide sequences determined in this study
have been deposited in GenBank under accession numbers
JN562755-JN563605.
Supporting Information
Figure S1 Compartmentalized R5 T cell-tropic HIV-1
populations in the CSF appear concurrently with the
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netic tree is displayed containing three sampling times for subject
7036. Months from HAD diagnosis correspond to the following
sample dates: 10/31/2002 (216), 4/28/2003 (210), and 2/18/
2004 (0). The genetic distance scale bar indicates the number of
nucleotide substitutions per site between env sequences. HIV-1 env
sequences selected for phenotypic analyses are indicated with a
black square.
(EPS)
Figure S2 Longitudinal assessment of CSF viral load
and CSF neopterin levels for subjects 7036 (A) and 7115
(B)prior to the diagnosisofHAD. Red asterisks denote sample
dates where HIV-1 population genotypes and phenotypes were
analyzed, and the black arrow denotes the day of HAD diagnosis.
(EPS)
Table S1 Phenotypic characteristics of HIV-1 Env-
pseudotyped reporter viruses.
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